Rhinitis Pipeline

DelveInsight’s, “Rhinitis Pipeline Insight, 2026” report provides comprehensive insights about 30+ companies and 32+ pipeline drugs in Rhinitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Rhinitis Understanding

Rhinitis Overview

Rhinitis is an inflammatory condition of the nasal mucosa characterized by symptoms such as nasal congestion, rhinorrhea (runny nose), sneezing, itching, and postnasal drip. It may be classified as allergic, infectious, or non-allergic/non-infectious rhinitis. Allergic rhinitis is one of the most common forms and occurs as part of a systemic allergic response involving the upper airway. Rhinitis can significantly affect quality of life, sleep, productivity, and may coexist with conditions such as asthma, sinusitis, and conjunctivitis.

The causes of rhinitis vary according to its subtype. Allergic rhinitis is triggered by exposure to airborne allergens such as pollen, dust mites, molds, animal dander, and cockroach allergens. Non-allergic rhinitis may result from environmental irritants (smoke, strong odors, pollution), temperature or humidity changes, hormonal fluctuations, certain medications, occupational exposures, or viral infections. In some individuals, genetic predisposition and atopy increase susceptibility to allergic rhinitis.

In allergic rhinitis, inhaled allergens stimulate an immunoglobulin E (IgE)-mediated immune response. Upon allergen exposure, mast cells degranulate and release inflammatory mediators such as histamine, leukotrienes, and prostaglandins. These mediators cause vasodilation, increased vascular permeability, mucus secretion, sneezing, itching, and nasal congestion. A later inflammatory phase involving eosinophils, basophils, and T-lymphocytes contributes to persistent mucosal inflammation and edema. Repeated exposure can lead to heightened nasal sensitivity to allergens and irritants.

The diagnosis of rhinitis is primarily clinical and based on a detailed medical history and physical examination. Key symptoms include sneezing, nasal congestion, rhinorrhea, and itching. For allergic rhinitis, confirmation can be obtained through allergy skin-prick testing or serum allergen-specific IgE testing. Additional evaluation may be necessary to differentiate rhinitis from sinusitis, nasal polyps, structural abnormalities, infections, or other causes of nasal obstruction. Diagnostic testing is particularly useful when symptoms are persistent, severe, or unresponsive to initial therapy.

Treatment depends on the underlying cause and severity of symptoms. For allergic rhinitis, avoidance of known allergens is recommended whenever possible. Intranasal corticosteroids are considered the most effective first-line therapy. Other options include antihistamines, leukotriene receptor antagonists, decongestants, saline nasal irrigation, and allergen immunotherapy (allergy shots) for selected patients. Management of non-allergic rhinitis focuses on avoiding triggers and using symptom-directed therapies. Appropriate treatment can substantially improve symptoms and reduce complications such as chronic sinusitis and sleep disturbances.

"Rhinitis Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Rhinitis pipeline landscape is provided which includes the disease overview and Rhinitis treatment guidelines. The assessment part of the report embraces, in depth Rhinitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Rhinitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Discover the latest Rhinitis pipeline insights, emerging therapies, and clinical advancements shaping the future of treatment in 2026.

Rhinitis Pipeline Report Highlights

The Rhinitis companies and academics are working to assess challenges and seek opportunities that could influence Rhinitis R&D. The therapies under development are focused on novel approaches to treat/improve Rhinitis.

Rhinitis Emerging Drugs Analysis

This segment of the Rhinitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Rhinitis Emerging Drugs

LP-003 Injection: Longbio Pharma

LP-003 Injection is a novel high-affinity, long-acting anti-IgE monoclonal antibody being developed for allergic diseases, including seasonal allergic rhinitis (SAR). The drug works by binding free immunoglobulin E (IgE) with very high affinity (reported as >100-fold higher binding affinity than some existing anti-IgE therapies), thereby preventing IgE from interacting with its receptors (FcεRI and FcεRII/CD23) on immune cells and inhibiting the IgE-mediated allergic inflammatory cascade responsible for rhinitis symptoms. LP-003 have more potent inhibition of IgE signaling and a longer duration of action than earlier anti-IgE therapies. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Rhinitis.

AK139 : Akeso

AK139 is a first-in-class bispecific antibody targeting IL-4Rα and ST2 that is being developed for multiple respiratory and autoimmune diseases, including allergic rhinitis. The drug's mechanism of action involves simultaneously blocking the IL-4/IL-13 signaling pathway through IL-4Rα inhibition and the IL-33/ST2 inflammatory pathway through ST2 inhibition. By suppressing these two key drivers of type 2 inflammation, AK139 is designed to reduce inflammatory cytokine release and inflammatory-cell infiltration associated with allergic rhinitis and other allergic respiratory diseases. Akeso describes AK139 as the world's first IL-4Rα/ST2 bispecific antibody to enter clinical development. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Rhinitis.

AJU-R713: AJU Pharm Co., Ltd.

AJU-R713 is an oral formulation of pranlukast hydrate, a leukotriene receptor antagonist being evaluated by AJU Pharm for perennial allergic rhinitis and bronchial asthma. Pranlukast works by selectively blocking cysteinyl leukotriene (CysLT1) receptors, thereby inhibiting the actions of leukotrienes (LTC4, LTD4, and LTE4), inflammatory mediators that contribute to nasal mucosal edema, mucus secretion, airway inflammation, and allergic symptoms associated with rhinitis. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Rhinitis.

Further product details are provided in the report……..

Rhinitis Drug Therapeutic Assessment

This segment of the report provides insights about the different Rhinitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Rhinitis Players in Rhinitis

There are approx. 30+ key companies which are developing the therapies Rhinitis. The companies which have their Rhinitis drug candidates in the most advanced stage, i.e. Phase III include, Longbio Pharma, and others.

Rhinitis Clinical Trial Phases

DelveInsight’s report covers around 32+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Rhinitis Drug Route of Administration

Rhinitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Rhinitis Product Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Rhinitis Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Rhinitis Clinical Trial Activities

The Rhinitis pipeline report provides insights into different Rhinitis clinical trials within phase II, I, preclinical and discovery stage. It also analyses Rhinitis therapeutic drugs key players involved in developing key drugs.

Rhinitis Pipeline Development Activities

The Rhinitis clinical Trial analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Rhinitis drugs.

Rhinitis Pipeline Report Insights

• Rhinitis Pipeline Analysis
• Rhinitis Therapeutic Assessment
• Rhinitis Unmet Needs
• Impact of Rhinitis Drugs

Rhinitis Pipeline Report Assessment

• Rhinitis Pipeline Product Profiles
• Rhinitis Therapeutic Assessment
• Rhinitis Pipeline Assessment
• Rhinitis Inactive drugs assessment
• Rhinitis Market Unmet Needs

Discover actionable insights into the Rhinitis market trends, epidemiology patterns, and forecast through 2036 to stay ahead in the evolving landscape of emerging therapies and treatment advancements.

Key Questions Answered In The Rhinitis Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Rhinitis drugs?
• How many Rhinitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Rhinitis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Rhinitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Rhinitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Rhinitis Key Players

• Longbio Pharma
• Genrix (Shanghai) Biopharmaceutical Co., Ltd.
• Prime Gene Therapeutics Co., Ltd.
• Ache Laboratorios Farmaceuticos S.A.
• Shanghai Mabgeek Biotech.Co.Ltd
• Jemincare
• Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
• Guangdong Hengrui Pharmaceutical Co., Ltd
• Akeso
• AJU Pharm Co., Ltd.

Rhinitis Key Products

• LP-003 Injection
• GR1802
• PG-011
• CM9241GRU
• MG-K10
• JYB1904
• TQH2722
• SHR-1819
• AK139
• AJU-R713

Explore comprehensive insights into Rhinitis epidemiology trends, patient population forecasts, and emerging growth opportunities through 2034 to support informed strategic decision-making and gain a competitive edge in the evolving healthcare landscape.